Answers are grounded in this paper and cite their sources.
OBJECTIVE: Tibolone is a synthetic steroid widely used for the treatment of menopausal symptoms and prevention of osteoporosis. Unlike conventional menopausal hormone therapy (MHT), tibolone is converted into metabolites with estrogenic, progestogenic and androgenic activity, and their relative availability may differ among tissues. Intracrinology, whereby circulating steroid precursors are locally converted into active hormones or inactive metabolites within target tissues, provides a potential framework for understanding these differential effects. This study aimed to critically examine the intracrinological basis of tibolone pharmacology and assess the extent to which tissue-specific metabolism may contribute to its differential clinical effects across estrogen-sensitive tissues. METHOD: A critical narrative review of experimental studies, randomized clinical trials and systematic reviews was conducted to evaluate tibolone metabolism and the distribution and activity of its metabolites in major target tissues, including breast, uterus, vagina, brain and bone. Experimental evidence indicates that tissue-specific differences in enzyme expression, sulfation, desulfation and possibly membrane transport may influence the local balance and availability of these metabolites. In breast and uterine tissues, preclinical studies suggest a predominance of sulfated metabolites, a pattern compatible with comparatively limited availability of unconjugated estrogenic metabolites. In bone and vaginal tissue, clinical benefits are compatible with sufficient local or systemic estrogenic activity. Evidence relating intracrinology to effects in the central nervous system remains limited and largely indirect. Across tissues, clinical outcomes are influenced by population characteristics, underlying pathology, dose and concomitant treatment, and do not directly establish the proposed metabolic mechanisms. CONCLUSION: Intracrinology provides a biologically plausible framework for understanding the tissue-selective effects of tibolone. However, clinical findings are largely compatible with, rather than confirmatory of, this mechanism, and the balance of benefits and risks appears to vary according to tissue, clinical context and individual patient characteristics.
No takes yet. Share an insight, caveat, or question.
Melo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: